A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
268actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-07 | actual | When the study began enrolling |
| Primary completion | 2025-12-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-16 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight or Obesity
Interventions
- Drug: MET097
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in body weight at Week 28
measured Baseline (Week 0) through Week 28 (Day 197)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed